What national promotion are you talking about?. There was little promotion by SNY! All they did is snuff it out and pulled back their own reps from promoting it. Where have you been, in some fantasyland? They put magazine articles out and sent out some samples - that pretty much sums up their marketing. There are a few benefits that will come out of this - the additional trials that are completed or in progress, and those will allow Mannkind to move forward, and hopefully advertise the product being truthful about it's superiority, timing, and soon to a broader base, such as children.
The only problem is that it has only had 3000 views when it should go viral.
I will say this. Mannkind may be limited in what they say, but Matthew Bendall is a marketing genius. He has found a way to SHOW both it's super fast superiority, and it's shelf-life - both label features the FDA has denied Mannkind in print.
I do not feel there would be anything illegal whatsoever, in demonstrating the truth in a time lapse coke challenge, nor his five month shelf life youtube.
It tells the truth. It is not breaking any rules to let the big screen show the truth, without stating anything outside the limits of what the FDA has imposed upon Mannkind's marketing of Afrezza in words or print. It is a REALITY commercial that is in no way illegal with proper disclaimers.
Place your Vote if you agree. It would provide the first to propel Afrezza to BlockBuster Status
It was nice on the call to see the termination date earlier first as July 5th moved up to early April. That is just eight weeks out and shaves off three months of shackles. Mannkind has a fighting chance at making a new destiny given this timeframe. This means Mannkind can market their product that much earlier to boost their numbers, and also begin receiving 100 percent of profit. Now I am sure Matt is working the other side ahead of the earnings call, on giving them some financial room to operate. He has these credentials and that is another thing obvious on the conference call in the exchange with GS, that this was a very active area - so much that he would not comment on it and he directed that piece to the earnings call.
For three months now, I cannot hide from a military flashlight deal on Yahoo - I still believe some effective internet marketing could do a lot to quickly boost numbers and build brand recognition. Where everywhere you surf, you are gaining awareness of Afrezza if you have diabetes - and surely there are ways to target diabetic patients in building that awareness.
AF trashed Facebook and Twitter, but both are areas where brand awareness can be built, and personal A1C results can be broadly disseminated. One HUGE thing Afrezza has going for it is that it works, and it will reduce the risk of nighttime lows - it will save lives.
This deal would make the most sense for both companies but seldom to you see the obvious advantage come to fruition, to the benefit of people with diabetes.
To me that simply means it is not a stock message board and they are taking out the disrespectful trash. Shorts can post all they want on a public stock message board. Glad to see them keeping things on a positive go-forward basis.
Flatlined all day long. Algo trading, and has not a thing to do with the value of the company. It is completely detached from reality. Interesting that the highest after hours trade at the days high of 1.10 was also the highest volume trade at over 42,000 shares.
As you can see form the message posted by straight-up -ask a sill question and you get a silly answer.
Thanks - meant to say Toujeo as the combo they must maintain control over. And it is Toujeo, not Lantus, that I have heard accounts of the shots burning to the point some have dis-continued use.
The truth staring SNY in the face is that the Tresiba/Afrezza combo will soon give most diabetics the closest opportunity they have ever had for a normal life. Lantus is inferior to Tresiba by some account (I cannot say yet with certainty, but I have heard of folks starting on Lantus and not being able to stay on it - the burn!), and it can only be masked to stand up against Tresiba if SNY controls the marketing and retains control of the pricing of the Lantus/Afrezza combination, riding the coattails of the control offered by Afrezza.
Soon it will be too late. Any leverage and control SNY had is soon to go bye-bye. I would not want to be SNY after the separation. Buyout of Afrezza by SNY IMO is still on the table.
Here's the deal, weeks ago SNY Threatens HUGE layoff's in the U.S. This is always needed to get politicians to pressure insiders - what's the issue!?. The label sucks and is proven innacurate by ALL users as well as clamp studies...get off the pot!, fix the label or the U.S. jobs are gone! State calls Federal, it's election time! FDA gets called to the carpet on the corrupt hit on Mannkind's initial label decisions.
Everyone knows it is super fast. Everyone knows it is superior, being monomeric and matched to that of a normal pancreas, Everyone knows it does not require refrigeration until the spares of a three-pack are opened (just to be cautious)...see Matt Bendal's test youtube!!! Afrezza will change diabetes. Game is over.
Matt flies over the pond.... SNY announces new layoffs in France...stars are aligning. Something good is about to occur. We will hear after stock or options cease trading - or perhaps they polish till the pre-scheduled conference tomorrow...we'll see.
Superiority, Super Fast Actin "Tinactin!", and Desert-proof (i.e. DO NOT REFRIGERATE UNTIL OPENED).
Read it and weep shorts
My vote - Tresiba/Affrezza combo to take over the entire market. For the sake of diabetics the world over. The killer combo is there for the taking.
A funny thought for sure! After seeing the "Coke Challenge" with Afrezza used by Matt on twitter - it is a video that deserves to go viral, and I think the idea should be used in an afrezza commercial. He again used the same coke challenge in the shelf life non-refrigeration test just last week - it is awesome and proves it is a life-changing diabetes treatment.
It also goes to show that Novo could own the entire diabetic market marketing a Tresiba/Afrezza combination - apparently a killer combo. The one chance SNY had in their hands to actually give Toujeo a chance for success, riding one the coattails of the control Afrezza offers, and they blew it.